Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course

- Sequencing analysis of MVK, NLRP3, TNFRSF1A, and PSTPIP1 genes
- Anti-TNF treatment in chronic kidney disease
- Lung nodules related using bDMARDs
- Biologics in rheumatic diseases: TURKBIO data
- A comparison of rituximab with cyclophosphamide
- Time course of rituximab-associated hypogammaglobulinemia
- How well are biologic and cDMARDs tolerated in PsA
Editor in Chief
George C. Tsokos
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Managing Editor
Ahmet Mesut Onat
Department of Rheumatology, Gaziantep Medical Park Hospital, Gaziantep, Turkey

Associate Editors
Xenofon Baraliakos
Department of Rheumatology, Ruhr-University Bochum, Bochum, Germany

Héctor Corominas
Servei de Reumatologia, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain

Guo-Min Deng
Department of Rheumatology, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Christian Hedrich
Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool School of Life Sciences, Liverpool, UK. Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK

Bünyamin Kısacık
Department of Rheumatology, Gaziantep Medical Park Hospital, Gaziantep, Turkey

Seung-Ki Kwok
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea

Vasileios C. Kyttaris
Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

Roger A. Levy
Department of Rheumatology, The State University of Rio de Janeiro, Rio De Janeiro, Brazil

Stmatis-Nick Liossis
Division of Rheumatology, University of Patras School of Medicine, Patras University Hospital, Patras, Greece

Pierre Miossec
Department of Immunology and Rheumatology, Edouard Herriot Hospital, Lyon, France

Konstantinos M. Parperis
Division of Rheumatology, Department of Medicine, University of Cyprus School of Medicine, Nicosia, Cyprus

Carlo Perricone
Rheumatology, Dipartimento di Medicina, University of Perugia, Perugia, Umbria, Italy

İsmail Sarı
Department of Rheumatology, Dokuz Eylül University School of Medicine, Izmir, Turkey

Amr H. Sawalha
Division of Rheumatology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA

Amir Sharabi
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Clinical Immunology, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel

Statistical Editor
İlker Ercan
Department of Biostatistics, Uludag University School of Medicine, Bursa, Turkey

Owner and Responsible Manager
Ahmet Mesut Onat
Professor in Rheumatology
Editorial Board

Julian Ambrus
Division of Allergy, Immunology and Rheumatology, Buffalo School of Medicine, Buffalo, NY, USA

Iannis Adamopoulos
Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis School of Medicine, California, USA

Nurullah Akkoç
Division of Rheumatology and Immunology, Department of Internal Medicine, Dokuz Eylül University School of Medicine, İzmir, Turkey

Sibel Zehra Aydin
Division of Rheumatology, Ottawa University School of Medicine, Ottawa, Canada

Ernest Brah
Department of Rheumatology, UCLA School of Medicine, CA, USA

Dimitrios Boumpas
Department of Internal Medicine and Rheumatology, Clinical Immunology and Allergy, University of Crete, Crete, Greece

Juan Jesus Gomez Reino Carnata
Division of Rheumatology, Department of Medicine, Hospital Clinico Universitario, Choupana, Santiago de Compostela, Spain

David D Cruz
Louise Coote Lupus Unit, St Thomas' Hospital, London, UK

Hanan Direskeneli
Department of Rheumatology, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey

Paul Emery
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Doruk Erkan
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Eugen Feist
Department of Rheumatology, Cooperation Partner of the Otto-von-Guericke University, Magdeburg, Germany

Cem Gabay
Division of Rheumatology, Geneva University Hospitals, Geneva, Italy

Francesco Del Galdo
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Conchi Castillo Gallego
Division of Rheumatology, Hospital Universitario La Paz, Madrid, Spain

Tamer A. Gheita
Department of Rheumatology, Cairo University School of Medicine, Giza, Egypt

Allan Gibofsky
Clinic of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Dennis McGonagle
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Vedat Hamuryudan
Division of Rheumatology, Department of Internal Medicine, Istanbul University School of Medicine, Istanbul, Turkey

Nicholas Manolios
Department of Rheumatology, Westmead Hospital, Sydney, Australia

Hilal Maradit Kremers
Department of Health Sciences Research, Collage of Medicine, Mayo Clinic, Minnesota, USA

Marco Mattucci-Cerinic
Department of Experimental and Clinical Medicine, Division of Rheumatology AOU, University of Florence, Florence, Italy

Pier Luigi Meroni
Department of Rheumatology, University of Milan Clinical Sciences and Community Health, Milan, Italy

Devyani Misra
Division of Gerontology and Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Peter Nash
Physician And Rheumatologist, University Of Queensland School of Medicine, Brisbane, QLD, Australia

Seza Özen
Division of Pediatric Rheumatology, Department of Child Health and Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Antonio Gonzales Martinez Pedroya
Division of Rheumatology, Department of Medicine, Hospital Clinico Universitario, Choupana, Santiago de Compostela, Spain

Claus Rasmussen
Department of Bioscience, Aarhus University, Aarhus, Denmark

Carlo Salvarani
Servizio di Reumatologia, Azienda Ospedaliera Arcispedale S. Maria Nuova, Emilia, Italy

Nancy Ann Shadick
Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

Yehuda Shoenfeld
Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Sekib Sokolovic
Clinic for Heart Diseases and Rheumatism, Clinical Center of University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Isaac Ely Stillman
Department of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

John H. Stone
Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Elias Toubi
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel

Konstantinos Tsilios
Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

Panayiotis Vlachoyiannopoulos
National and Kapodistrian University of Athens, Athens, Greece

Alvin Wells
Board-certified Rheumatologist Director, Rheumatology and Immunotherapy Center, Franklin, WI, USA

Hasan Yazıcı
Department of Rheumatology, Istanbul University School of Medicine, Istanbul, Turkey
AIMS AND SCOPE

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The aim of the European Journal of Rheumatology is to cover various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case based reviews, letters to the editor and images in rheumatology. The publication language of the journal is English.

The journal’s target audience includes academicians, practitioners, specialists and students from all disciplines of rheumatology.

European Journal of Rheumatology adheres to the principles outlined by the guidelines of ICMJE, WAME, EASE and COPE.

European Journal of Rheumatology is currently indexed in PubMed Central, Web of Science-Emerging Sources Citation Index, EBSCO and CINAHL, and Gale.

All published content of the European Journal of Rheumatology is available online at eurjrheumatol.org, free of charge.

Statements or opinions expressed in the manuscripts published in the European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

European Journal of Rheumatology is an open access publication and the journal's publication model is based on Budapest Open Access Initiative (BOAI) declaration. Journal's archive is available online, free of charge at eurjrheumatol.org. European Journal of Rheumatology content is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Reprint requests and requests concerning advertising should be addressed to the publisher;

Publisher: AVES
Address: Büyükdere Cad. 105/9 34394 Şişli, İstanbul, Turkey
Phone: +90 212 217 17 00
e-mail: info@avesayincilik.com
avesayincilik.com
INSTRUCTIONS TO AUTHORS

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access, peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The journal covers various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoimmune inflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology. The publication language of the journal is English.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Manuscripts submitted to European Journal of Rheumatology will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors’ responsibility to carefully protect the patients’ anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

All submissions are screened by a similarity detection software (iThenticate by CrossCheck).

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

European Journal of Rheumatology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through www.eurjrheumatol.org) during the initial submission process in order to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of "gift authorship," the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding
MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2019 - http://www.icmje.org/icmje-recommendations.pdf). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behaviour.

Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system, available at www.eurjrheumatol.org. Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:
• Copyright Agreement and Acknowledgement of Authorship Form, and
• ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors)
during the initial submission. These forms are available for download at www.eurjrheumatol.org.

Preparation of the Manuscript

Title page: A separate title page should be submitted with all submissions and this page should include:
• The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
• Name(s), affiliations, and highest academic degree(s) of the author(s),
• Grant information and detailed information on the other sources of support,
• Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
• Acknowledgement of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: An abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Original Articles should be structured with subheadings (Objective, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.

Preprint

European Journal of Rheumatology does not consider preprint publications as prior publication. In other words, authors are allowed to present and discuss their findings on a non-commercial preprint server before submission to a journal.

Authors must provide the journal with the pre-print server deposit of their article accompanying its DOI during initial submission.

If the article is published in the European Journal of Rheumatology, it is the responsibility of the authors to update the archived preprint and link it to the published version of the article.
Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).

Main Points: All submissions except letters to the editor and images in rheumatology should be accompanied by 3 to 5 “main points” which should emphasize the most noteworthy results of the study and underline the principle message that is addressed to the reader. This section should be structured as itemized to give a general overview of the article. Since “Main Points” targeting the experts and specialists of the field, each item should be written as plain and straightforward as possible.

Manuscript Types
Original Articles: This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Methods, Results, and Discussion subheadings. Please check Table 1 for the limitations for Original Articles.

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner M, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J. 1983;7:1489-1493). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

Review Articles: Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

Case-based Reviews: Case-based reviews are reports on rare cases or conditions that constitute challenges in diagnosis and treatment, incorporating a mini literature review of a particular area of the field. Please check Table 1 for the limitations for Case-based Reviews.

Letters to the Editor: This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers’ attention, particularly educative cases, may also be submitted in the form of a “Letter to the Editor.” Readers can also present their comments on the published manuscripts in the form of a “Letter to the Editor.” Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

Images in Rheumatology: This type of submissions should present a striking image that may challenge and inform readers and contribute to their education. Please check Table 1 for the limitations for Images in Rheumatology.

Table 1. Limitations for each manuscript type

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>Word limit</th>
<th>Abstract word limit</th>
<th>Reference limit</th>
<th>Table limit</th>
<th>Figure limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Article</td>
<td>3000</td>
<td>400 (Structured)</td>
<td>35</td>
<td>6</td>
<td>7 or total of 15 images</td>
</tr>
<tr>
<td>Review Article</td>
<td>5000</td>
<td>250</td>
<td>50</td>
<td>6</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Case-based Reviews</td>
<td>2400</td>
<td>200</td>
<td>30</td>
<td>No tables</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>500</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>No media</td>
</tr>
<tr>
<td>Images in Rheumatology</td>
<td>500</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>4 or total of 8 images</td>
</tr>
</tbody>
</table>
the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 x 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: “Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)”

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

References
Both in-text citations and the references must be prepared according to the AMA Manual of Style. While citing publications, preference should be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided. Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first three authors should be listed followed by ‘et al.’ In the main text of the manuscript, references should be cited in superscript after punctuation. The reference styles for different types of publications are presented in the following examples.


CONTENTS

Original Articles

62 Next-Generation Sequencing Analysis of MVK, NLRP3, TNFRSF1A, and PSTPIP1 Genes in Patients without MEFV Gene Variation and Genotype–Phenotype Correlation
Gamze Vuran, Afig Berdeli

68 Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?
Belkıs Nihan Coşkun, Burcu Yağız, Seniha Gündüz Çorabay, Yavuz Pehlivan, Ediz Dalkılıç

75 Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

82 A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry

88 A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study
Maryam Tavakoli Chaleshtori, Ziba Faraizadegan, Mansour Salesi

93 Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
Anam Taqi, Ayobami Akemuye, Antoine Azar, Philip Seo, Duvuru Geetha

100 How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
Issrah I. Jawad, Muhammed K. Nisar

Images in Rheumatology

104 Pigmented villus fragments on synovial fluid examination
Ufuk Iğen, Hakan Emmungil

106 Iatrogenic Cushing’s syndrome from topical steroid use
Vivek Arya, Ashish Sharma, Mohammad Ali
CONTENTS

Case-based Review

Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature
Brigitte Kazzi, Brent Gudenkauf, Derek Fine, Jose Manuel Monroy-Trujillo, Antoine Azar, Gabriel Giannini, Homa Timlin

Sitagliptin-induced Achilles enthesopathy: Case report and literature review
İbrahim Halil Rızvanoğlu, Bünyamin Kısacık

Letter to the Editor

Screening for Leishmania specific antibodies among patients with rheumatic diseases treated with biological therapy
Fruzsina Szabados, Henrik Vedel Nielsen, Kurt Fuursted, Asta Linauskas, Claus Rasmussen, Peter Derek Christian Leutscher